A Form 4 filing with the Securities and Exchange Commission shows that Walters Group, a 10%+ owner of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), purchased 4,335,000 shares of the company’s common stock on August 14, 2026. The transaction was an open-market purchase, meaning the insider used its own capital to acquire the shares rather than receiving … Read more
A newly filed Form 4 shows PM Alpha II DAC, a 10%-plus owner of AB Private Lending Fund (AB-Lend), purchased 53,060 shares of the fund on the open market on March 2, 2026. The transaction was priced at $24.99 per share, for a total outlay of $1,325,964.98. This was a straightforward open-market buy, meaning the … Read more
Catalyst4, Inc., an insider at MapLight Therapeutics, Inc. (MLPT), disclosed a fresh open-market purchase in a Form 4 filing with the SEC. The transaction, dated August 14, 2026, shows Catalyst4 buying 4,400,000 shares at $11.38 apiece, a total outlay of $50,072,000.00 paid with the insider’s own funds. Following the purchase, Catalyst4 reports beneficial ownership of … Read more
A filing with the SEC shows Audax Private Credit Business, LP, an insider of Audax Private Credit Fund, LLC, purchased 575,161 shares on the open market on August 12, 2026. The purchase price was $24.56 per share, for a total outlay of $14,124,234.89. Following the transaction, the insider’s indirect holdings, held through an entity structure … Read more
Intel Corporation (NASDAQ: INTC) CEO and Director Tan Lip-Bu disclosed an open-market purchase of company stock in a Form 4 filing tied to a transaction dated August 11, 2026. The filing shows Tan bought 105,263 shares at $95.00 apiece, a purchase totaling $9,999,985.00 — just shy of the $10 million mark. Following the transaction, Tan’s … Read more
A newly filed Form 4 shows Ghiath M. Sukhtian, an insider at Outlook Therapeutics, Inc. (OTLK), made a substantial open-market purchase of company stock. According to the filing, the transaction was dated August 12, 2026, and involved the purchase of 2,525,252 shares at a price of $0.99 per share, for a total outlay of $2,499,999.48. … Read more
A fresh Form 4 filing shows Carl L. Gordon, a director of BlossomHill Therapeutics, Inc. (BLSM), purchased 625,000 shares of the company on the open market on August 10, 2026. The transaction, priced at $16.00 per share, totaled $10,000,000.00 — a purchase made with the insider’s own funds rather than acquired through options or other … Read more
A director of BlossomHill Therapeutics, Inc. (BLSM) put real money on the table this week. According to a Form 4 filing, OrbiMed Advisors LLC purchased 625,000 shares of BlossomHill on August 10, 2026, in an open-market transaction priced at $16.00 per share. The total outlay came to an even $10,000,000.00, funded directly by the insider … Read more
A newly filed Form 4 with the Securities and Exchange Commission shows that Bankers Life & Casualty Co., acting in its capacity as a 10%+ owner, purchased a substantial block of shares in Privacore VPC Asset Backed Credit Fund on August 7, 2026. The filing shows no ticker symbol associated with the fund, consistent with … Read more
Aptiv PLC (APTV) Chair and CEO Kevin P. Clark disclosed an open-market purchase of 51,190 shares on August 10, 2026, according to a Form 4 filing with the SEC. The shares were bought at $48.89 apiece, for a total outlay of $2,502,684.22. Following the transaction, Clark holds 651,016 shares directly, a stake that reflects a … Read more
Foresite Capital Management V, LLC, a 10%+ owner of Latigo Biotherapeutics, Inc. (LTGO), disclosed an open-market purchase of 140,000 shares on August 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at $18.00 apiece, for a total transaction value of $2,520,000.00. This was a straightforward open-market … Read more
A newly filed Form 4 shows James B. Tananbaum, an insider at Latigo Biotherapeutics, Inc. (LTGO), purchased 140,000 shares of the company on the open market on August 10, 2026. The transaction was executed at $18.00 per share, for a total outlay of $2,520,000.00 out of the insider’s own funds. Unlike option exercises or grants … Read more